Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
VIR-7831 Suffers Setback In NIH Study
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
You may also be interested in...
Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.